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A b s t r a c t
This study aimed to estimate and analyze the
p re valence of cervical intraepithelial neopla-
sia (CIN) and inva s i ve cervical carc i n o m a
based on cytological diagnosis. The study in-
cluded 120,635 women undergoing cytological
exams in public health services in the re g i o n
of Ca m p i n a s , São Paulo St a t e , Bra z i l , b e t w e e n
September 1998 and Ma rch 1999. Pre va l e n c e
rates per 100,000 women were : 354 for CIN I;
255 for CIN II; 141 for CIN III; and 24 for inva-
s i ve carc i n o m a . As age incre a s e d , p re va l e n c e
rates and pre valence ratios decreased for CIN
g rades I and II and increased for CIN III until
the 50-54 age gro u p, d e c reasing thereafter The
p re valence rate of inva s i ve carcinoma in-
c reased with age. The pre valence pattern of
CIN II was distinct from that of CIN III, b u t
similar to that of CIN I. This would not have
been observed if the Bethesda System had been
used for cytological diagnosis. Mean age at
time of CIN II diagnosis was about 10 years
less than for CIN III diagnosis. T h e re f o re , a
h i g h - g rade lesion diagnosed in a young w o m a n
a c c o rding to the Bethesda System would pro b-
ably be a CIN II, w h e reas in an older woman it
would probably be a CIN III.
Ce rvical In t raepithelial Ne o p l a s i a ; Ut e r i n e
Ne o p l a s m s ; Pre va l e n c e
I n t ro d u c t i o n
Ce rvical cancer, with its high incidence, is an
i m p o rtant cause of death in developing coun-
t ri e s, where socioeconomic conditions are pre-
c a rious and screening pro g rams do not ade-
quately achieve their goals 1.
Ce rvical cancer screening in Campinas be-
gan in 1968. Since the beginning, the scre e n i n g
model established that Pap smear sample col-
lection would be decentra l i zed and that the Cy-
tology Labora t o ry at the State Un i versity in
Campinas (UNICAMP) would be centra l i ze d .
Gra d u a l l y, screening extended to other munici-
pal districts of the region, UNICAMP being the
main re f e rence center for assisting women fro m
community health centers who had been iden-
tified as having abnormal Pap test results 2.
Until 1998 there we re no data on the pre va-
lence rate of cervical intraepithelial neoplasia
(CIN) among the population in the region of
Ca m p i n a s. The data available re f e r red to the
total number of exams perf o rmed in re g i o n a l
cytological labora t o ri e s, which only discri m i-
nated between positive and negative re s u l t s.
T h e re f o re, information on age-specific pre va-
lence was not ava i l a b l e. In addition, until that
year no population data we re available on age-
specific pre valence rates of cervical intra e p-
ithelial lesions in other regions of Bra z i l .
This study thus aimed to estimate the p re va-
lence rate of cervical intraepithelial lesions and
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i n va s i ve cervical carcinoma based on cytologi-
cal diagnosis, as well as to analyze trends ac-
c o rding to age at time of diagnosis.
Subjects and methods
This cross-sectional study was aimed at a fe-
male population of public health system c l i e n t s
f rom 64 cities situated in the region of Ca m p-
i n a s, who we re submitted to a Pap test for cer-
vical cancer screening. Ca m p i n a s, a city in the
State of São Paulo with a population of approx-
imately one million, is the hub of regional eco-
nomic and university activities. The re g i o n
s c reened for cervical cancer has approx i m a t e l y
t h ree and a half million inhabitants. It is esti-
mated that almost 60% of the re g i o n’s popula-
tion depends on the public health system, m o s t-
ly re p resented by the lower socioeconomic
population. The samples were collected in c o m-
munity health units under local superv i s i o n .
Cu r rent health policy suggests screening w o m e n
b e t ween ages 25 and 60 eve ry three ye a r s, after
two normal tests perf o rmed at one-year inter-
vals. Many of these municipal districts now h a ve
their own colposcopy clinics.
The study population included 131,207
women receiving Pap smears for cervical can-
cer screening in public health services betwe e n
September 1998 and Ma rch 1999, whose slides
had been processed and examined at the UNI-
CAMP Cytology Labora t o ry. This Labora t o ry is
responsible for approximately 70% of the cyto-
logical exams perf o rmed by the public health
system in the Campinas re g i o n .
The study excluded pregnant women ( 5 , 2 7 8 ) ,
those submitted to hysterectomy (3,472), and
those of unknown or inconsistent ages (3,232).
The same woman could present more than one
e xclusion cri t e rion. When a woman underwe n t
repeat tests during the study period, only the
result of the first test was considered. Thus a
total of 120,635 women met the inclusion cri t e-
ria and we re admitted to the study.
The classification proposed by Richart 3 f o r
c e rvical intraepithelial neoplasia was used in
this study because the goal was to study CIN
g rades II and III separa t e l y. Samples we re col-
lected with an Ay re spatula and cytobru s h .
Data we re collected from the Pap test form
adopted by the Cytology Labora t o ry and ava i l-
able in all public health serv i c e s, designed for
reading on optical mark re a d e r s. This form was
i n t roduced in August 1998 after a deve l o p m e n t
p e riod and perf o rmance test in two communi-
ty outpatient clinics. The first month that this
f o rm was used was dedicated to identifying
system errors and difficulties met by the com-
munity health centers. Du ring this period a
c o m p u t e r-based system was developed to de-
tect data incompatibility or inconsistencies
d u ring the form’s optical reading. Fo rms pre-
senting incompatibilities and inconsistencies
we re rejected. The system could accept only
one cytological diagnosis for each cell type, ei-
ther squamous or glandular, in addition to the
diagnosis of “cytopathic effect suggestive of
H P V”.
Pre valence rates for each cytological diag-
nosis and the pre valence ratio (PR) with 95%
confidence interval (CI) we re calculated ac-
c o rding to age at diagnosis. The re f e rence g ro u p
for CIN PR was women aged 19 or younger and
for inva s i ve carcinoma PR was women aged 20
to 24, since no diagnosis of this lesion was ob-
s e rved in the group aged 19 or yo u n g e r. Linear
PR va riations with increasing age group we re
tested using the Co c h ra n - A rmitage Trend Test 4.
R e s u l t s
Some 20% of the women we re under 25 ye a r s
of age and two-thirds we re 39 or yo u n g e r, while
only 5.4% we re over 59. Ap p roximately 50% of
the women undergoing a Pap smear for the
first time we re under 25 (Fi g u re 1). Almost one-
sixth (19,635) of the women we re receiving t h e i r
first Pap smear, and 40%, 19.9%, 8.7%, and 6 . 2 %
we re repeating the test, after one-, two-, thre e - ,
and more than five - year interva l s, re s p e c t i ve l y
(data not show n ) .
Mean ages at cytological diagnoses we re
28.0, 29.3, 38.1, and 51.7 years for CIN grades I,
II, III, and inva s i ve carcinoma, re s p e c t i ve l y. Fo r
all diagnoses, the 50t h age percentile va ri e d
f rom one to three years below the mean age
(Table 1).
The ove rall pre valence rate of intra e p i t h e-
lial and inva s i ve lesions was 774 per 100,000
women. Pre valence rates we re 354 per 100,000
women for CIN I, 255 for CIN II, 141 for CIN III,
and 24 for inva s i ve carcinoma (Table 2).
Ac c o rding to the Co c h ra n - A rmitage Tre n d
Test, pre valence ratios for CIN grades I and II
d e c reased significantly as age increased. Co n-
ve r s e l y, pre valence ratios for CIN III and inva-
s i ve carcinoma presented an upw a rd trend as
age increased, despite a slight decrease in CIN
III above 50-54 ye a r s. Pre valence ratios for CIN
I we re less than 0.10 for the 50-54 age group or
o l d e r. The highest CIN III pre valence ratio was
in the 50-54-year group (Table 3).
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D i s c u s s i o n
Data from 1988 for the State of São Pa u l o, Bra z i l ,
on pre valence rates of cervical lesions showe d
860 CIN I per 100,000 cytological tests, 270 CIN II
per 100,000, 160 CIN III per 100,000, and 70 inva-
s i ve carcinomas per 100,000 tests. This database
re g i s t e red 170,754 tests in 120,604 women. So m e
women thus had repeat tests. Fu rt h e rm o re, there
was no information as to whether tests from the
c e rvical pathology outpatient clinic had been ex-
cluded. These tests could bias estimates of the
p re valence rates due to the higher number of ab-
n o rmal cytological tests in this group of women.
T h e re is also no information on the va riability of
CIN pre valence rates according to age 5.
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Brazilian data from the cervical cancer
s c reening information system of the He a l t h
Mi n i s t ry (SISCO LO) for the year 2000 showe d
2,262, 383, and 54 per 100,000 Pap tests with
cytological diagnoses of low - g rade squamous
i n t raepithelial lesion (LSIL), high-grade squa-
mous intraepithelial lesion (HSIL), and inva-
s i ve cervical cancer, re s p e c t i vely 6. The LSIL
diagnosis of the Bethesda System includes the
R i c h a rt CIN I diagnosis 3 plus the HPV cyto-
logical diagnosis, and there f o re there is no
e q u i valent diagnosis in our study. The HSIL
cytological diagnosis of the Bethesda Sy s t e m
is equivalent to the combined diagnoses of
CIN grades II and III 7. T h u s, the HSIL pre va-
lence rate in the Brazilian data could be con-
Table 1
Mean and percentile of age (years) according to cytological diagnosis.
2 5t h p e rc e n t i l e 5 0t h p e rc e n t i l e 7 5t h p e rc e n t i l e Mean (SD) Total women
CIN I 2 0 2 5 3 4 28.0 (9.7) 4 2 7
CIN II 2 2 2 7 3 5 29.3 (9.5) 3 0 8
CIN III 2 8 3 7 4 6 38.1 (12.1) 1 7 0
Invasive carc i n o m a 4 3 4 9 5 9 51.7 (14.7) 2 9
Total women 2 6 3 4 4 3 35.7 (12.8) 1 2 0 , 6 3 5
CIN = cervical intraepithelial neoplasia.
F i g u re 1
Distribution (%) of total screened women (n = 120,635 women) and the women doing first 
Pap test (n = 19,304) by age gro u p .
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s i d e red similar to the CIN II plus CIN III p re va-
lence rates observed in this study, i.e., 396 per
1 0 0 , 0 0 0 .
S I S CO LO data from the State of Pa ra n á ,
Brazil, from Ja n u a ry to October 2002 showe d
p re valence rates for CIN grades I, II, and III of
262, 249, and 124 per 100,000 women, re s p e c-
t i vely 8, and the data are similar to those ob-
tained in the current study. The SISCO LO re-
p o rts consulted had no information ava i l a b l e
on age-specific pre valence ra t e s.
Other studies have shown pre valence ra t e s
for ove rall abnormal cytological diagnoses f ro m
s c reening pro g rams in different countri e s. In
two studies in Holland, rates of abnormal Pa p
t e s t s, including all abnormal diagnoses, we re
540 per 100,000 9 and 800 per 100,000 1 0. In
Thailand, 1,250 abnormal cytological diag-
noses per 100,000 women 1 1 and in Chile 1,430
a b n o rmal cytological diagnoses per 100,000
women we re observed 1 2. Mo re re c e n t l y, a s t u d y
in a ru ral Costa Rican population showed a
Table 3
P revalence ratio of CIN and invasive carcinoma by age gro u p .
Age gro u p CIN I CIN II CIN III Invasive carc i n o m a
P R 95% CI P R 95% CI P R 95% CI P R 95% CI
< 19 1 . 0 0 – 1 . 0 0 – 1 . 0 0 – – –
2 0 - 2 4 0 . 6 8 0 . 5 2 - 0 . 9 0 0 . 7 5 0 . 5 2 - 1 . 1 0 3 . 1 1 0 . 9 2 - 1 0 . 5 7 1 . 0 0 –
2 5 - 2 9 0 . 3 6 0 . 2 6 - 0 . 5 0 0 . 6 9 0 . 4 8 - 1 . 0 2 4 . 2 8 1 . 3 0 - 1 4 . 1 6 0 . 9 5 0 . 0 2 - 3 6 . 4 0
3 0 - 3 4 0 . 3 6 0 . 2 6 - 0 . 5 1 0 . 5 6 0 . 3 8 - 0 . 8 4 4 . 3 1 1 . 3 0 - 1 4 . 3 0 1 . 9 9 0 . 0 9 - 4 6 . 8 0
3 5 - 3 9 0 . 3 0 0 . 2 1 - 0 . 4 3 0 . 3 8 0 . 2 5 - 0 . 5 9 4 . 9 9 1 . 5 2 - 1 6 . 3 9 – –
4 0 - 4 4 0 . 1 6 0 . 1 0 - 0 . 2 6 0 . 2 3 0 . 1 3 - 0 . 4 1 3 . 8 2 1 . 1 3 - 1 2 . 9 6 7 . 3 5 0 . 4 6 - 1 1 8 . 8 7
4 5 - 4 9 0 . 2 1 0 . 1 4 - 0 . 3 5 0 . 3 1 0 . 1 8 - 0 . 5 5 6 . 0 0 1 . 7 9 - 2 0 . 1 4 8 . 2 6 0 . 4 9 - 1 3 8 . 9 2
5 0 - 5 4 0 . 0 6 0 . 0 2 - 0 . 1 8 0 . 2 7 0 . 1 4 - 0 . 5 7 7 . 5 8 2 . 2 1 - 2 6 . 0 3 1 0 . 9 6 0 . 6 2 - 1 9 5 . 2 6
5 5 - 5 9 0 . 1 0 0 . 0 4 - 0 . 2 7 0 . 1 4 0 . 0 4 - 0 . 4 5 4 . 3 1 . 0 8 - 1 7 . 3 1 1 2 . 5 1 0 . 6 4 - 2 4 4 . 9 6
> 60 0 . 0 3 0 . 0 1 - 0 . 1 3 – – 3 . 6 8 0 . 9 8 - 1 3 . 8 8 1 8 . 6 2 1 . 1 9 - 2 9 2 . 3 5
C AT T - 1 2 . 5 2 - 8 . 8 1 2 . 6 1 5 . 8 8
p < 0.001 p < 0.001 p < 0.01 p < 0.001
PR = prevalence ratio; CIN = cervical intraepithelial neoplasia; CI = confidence interval; CATT = Cochran-Armitage Trend Test 4. 
T h e re were no invasive carcinoma cases among women in the “19 years and under” and “35-39 year” age gro u p s .
Table 2
P revalence (per 100,000 women) of CIN and invasive carcinoma by age-gro u p .
Age gro u p CIN I CIN II CIN III Invasive carc i n o m a Total women
n P re v a l e n c e n P re v a l e n c e n P re v a l e n c e n P re v a l e n c e
£ 19 8 6 9 5 8 4 6 5 1 2 3 3 3 0 0 8 , 9 7 7
2 0 - 2 4 1 1 3 6 5 3 6 7 3 8 7 1 8 1 0 4 1 7 1 7 , 2 9 5
2 5 - 2 9 6 3 3 4 7 6 5 3 5 8 2 6 1 4 3 1 6 1 8 , 1 4 7
3 0 - 3 4 6 1 3 5 2 5 0 2 8 9 2 5 1 4 4 2 1 2 1 7 , 3 2 6
3 5 - 3 9 5 0 2 8 8 3 4 1 9 6 2 9 1 6 7 0 0 1 7 , 3 7 7
4 0 - 4 4 2 2 1 5 6 1 7 1 2 1 1 8 1 2 8 6 4 3 1 4 , 1 0 0
4 5 - 4 9 2 2 2 1 0 1 7 1 6 3 2 1 2 0 1 5 4 8 1 0 , 4 5 9
5 0 - 5 4 4 6 3 9 1 4 3 1 6 2 5 4 4 6 3 6 , 3 0 9
5 5 - 5 9 4 9 7 3 7 2 6 1 4 5 3 7 2 4 , 1 4 5
‡ 60 2 3 1 0 0 8 1 2 3 7 1 0 8 6 , 5 0 0
Total women 4 2 7 3 5 4 3 0 8 2 5 5 1 7 0 1 4 1 2 9 2 4 1 2 0 , 6 3 5
CIN = cervical intraepithelial neoplasia.
P R E VALENCE OF CIN AND INVASIVE CARCINOMA 1 5 7
Cad. Saúde Pública, Rio de Janeiro, 20(1):153-159, jan-fev, 2004
p re valence rate of abnormal Pap tests of 2.2%
LSIL and 1.5% HSIL 1 3. An American study in-
cluded 628,085 women, almost half of whom
f rom ethnic minority gro u p s. Pre valence ra t e s
of abnormal results we re 3.2%, 3.0%, and 2.7%,
re s p e c t i ve l y, among blacks, whites, and Hi s-
p a n i c s, according to the Bethesda System 1 4.
Re s e a rch using the Bethesda System has
s h own a higher pre valence rate than the cur-
rent study and others. In fact, the Bethesda Sy s-
tem includes atypical squamous cells of unde-
t e rmined significance, atypical glandular cells
of undetermined significance, and HPV cyto-
logical diagnoses, which increase the ove ra l l
p re valence of abnormal results 7. These diag-
nostic classes do not exist in the Richart system 3.
At any ra t e, pre valence rates of cervical in-
t raepithelial lesions, re g a rdless of classifica-
tion, present widely va ried va l u e s. This may be
a t t ributed to cervical cancer screening, dive r s e
collection techniques, quality of samples, and
especially differences in diagnostic cri t e ria. In
addition, all pre valence rates mentioned are
c rude rates that do not consider the differe n c e
in age distribution for each population.
The decreasing range of pre valence ra t e s
for CIN grades I and II according to age ob-
s e rved in this study was wider than the incre a s-
ing range in pre valence rates for CIN III or in-
vasive carcinoma. Therefore, the decrease in t h e
p re valence rates of CIN grades I and II could be
due mainly to cytological screening or sponta-
neous re g ression of these lesions, rather than
p ro g ression to more seve re diagnoses 1 5. T h e
d e c reasing trend of pre valence rates for CIN
g rades I and II is consistent with a higher HPV
infection rate among younger women and s p o n-
taneous cure with follow-up time 1 3 , 1 6 , 1 7.
On the other hand, CIN III is associated with
persistent oncogenic HPV infection 1 8 , 1 9. Co m-
p a red to CIN grades I and II, CIN III has a lowe r
p e rcentage of spontaneous re g ression and a
higher percentage of pro g ression to inva s i ve
c a rcinoma 1 5. Fu rt h e rm o re, the mean estimat-
ed duration of CIN III is approximately 10 ye a r s,
meaning that there is a cumulative annual inci-
dence which influences the pre valence rates 2 0.
CIN III pre valence peaked in the 55 to 59
age group and decreased in the older age g ro u p s,
and this trend could be due to spontaneous re-
g ression or pro g ression to inva s i ve carc i n o m a
in this age group 1 5. Treatment of CIN III could
also lead to a decrease in its pre valence ra t e
due to cervical cancer screening. Data from Swe-
den, Canada, United St a t e s, and Great Bri t a i n
p resented a peak pre valence for in situ carc i-
noma between ages 35 and 40, thus earlier
than the peak found in Campinas 2 1. Howe ve r,
these countries had established their cerv i c a l
cancer screening pro g rams earlier and for sev-
eral decades in a more systematic way. As a c o n-
s e q u e n c e, the pre valence rate peaked in yo u n g e r
women and its decline was earlier and more
a b rupt, possibly due to earlier detection and
efficient treatment of these lesions.
As previously mentioned, the Bethesda Sy s-
tem considers the combined diagnoses of CIN
g rades II e III as HSIL. But the pre valence ra t e
of CIN II according to age is similar to that of
CIN I and different from that of CIN III, which
would not have been observed if the Be t h e s d a
classification had been used. Also, mean age at
the time CIN grades I and II we re diagnosed
was similar and about 10 years younger than
the mean age in which CIN III was diagnosed.
T h e re f o re, an HSIL diagnosed in a yo u n g
woman would probably be a CIN II. If it we re
diagnosed in a woman over 50, it would pro b a-
bly be a CIN III. Results observed by He r re ro et
al. 1 3 in his population-based study in a ru ra l
Costa Rican population emphasize this possi-
b i l i t y, since the pre valence rate of HSIL pre-
sented two peaks, the first around age 30, pos-
sibly due to CIN II, and the second around age
65, possibly due to CIN III.
Although this is not a population-based
s t u d y, the results re p resent a significant sam-
ple of the user population of the Brazilian pub-
lic health system. T h e re f o re, these estimates
should be close to the actual values of a lowe r-
income population and could provide a re f e r-
ence for planning, assessment, and follow - u p
of cervical cancer screening activities.
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R e s u m o
O objetivo deste estudo foi estimar e analisar a pre va-
lência das neoplasias intra-epiteliais cervicais (NIC) e
do carcinoma inva s i vo do colo uterino, com base no
diagnóstico citológico. Fo ram incluídas 120.635 mu-
l h e res que re a l i z a ram o exame citológico, e n t re setem-
b ro de 1998 a março de 1999, nos serviços públicos de
saúde da região de Ca m p i n a s , Bra s i l . As pre va l ê n c i a s
por 100 mil mulheres fora m : 354 para NIC I; 255 para
NIC II; 141 para NIC III e 24 de carcinoma inva s i vo. À
medida que a idade aumentou, as pre valências e ra-
zões de pre valência diminuíram para NIC I e NIC II, e
a u m e n t a ram para NIC III até 50-54 anos, d e c re s c e n d o
a p ó s . A pre valência do carcinoma inva s i vo aumentou
com a idade. O padrão da pre valência da NIC II é dis-
tinto do padrão da NIC III e semelhante ao da NIC I, o
que não teria sido observado se fosse utilizado o Si s t e-
ma de Be t h e s d a .A i n d a , a média da idade ao diagnós-
tico da NIC II foi cerca de dez anos menor que para
NIC III. Po rt a n t o, um diagnóstico de lesão de alto
g ra u , de acordo com o Sistema de Be t h e s d a , em uma
mulher jovem prova velmente seria NIC II e em uma
mulher mais velha seria NIC III.
Neoplasia In t ra-epitelial Ce rv i c a l ; Neoplasias Ut e r i-
n a s ; Pre va l ê n c i a
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